TherapeuticsMD Inc (NASDAQ: TXMD)’s stock price has plunge by -6.37relation to previous closing price of 1.57. Nevertheless, the company has seen a 34.86% surge in its stock price over the last five trading sessions. benzinga.com reported 2024-08-26 that The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects.
Is It Worth Investing in TherapeuticsMD Inc (NASDAQ: TXMD) Right Now?
The 36-month beta value for TXMD is at 1.12. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TXMD is 11.34M, and currently, shorts hold a 0.19% of that float. The average trading volume for TXMD on January 06, 2025 was 146.16K shares.
TXMD’s Market Performance
TXMD stock saw an increase of 34.86% in the past week, with a monthly gain of 9.26% and a quarterly increase of -8.13%. The volatility ratio for the week is 49.61%, and the volatility levels for the last 30 days are 16.44% for TherapeuticsMD Inc (TXMD). The simple moving average for the last 20 days is 24.02% for TXMD stock, with a simple moving average of -15.43% for the last 200 days.
TXMD Trading at 8.78% from the 50-Day Moving Average
After a stumble in the market that brought TXMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.55% of loss for the given period.
Volatility was left at 16.44%, however, over the last 30 days, the volatility rate increased by 49.61%, as shares surge +11.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.96% lower at present.
During the last 5 trading sessions, TXMD rose by +34.86%, which changed the moving average for the period of 200-days by -35.81% in comparison to the 20-day moving average, which settled at $1.1853. In addition, TherapeuticsMD Inc saw 70.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXMD starting from Collins Cooper C., who purchase 4,094 shares at the price of $1.73 back on Aug 22 ’24. After this action, Collins Cooper C. now owns 52,016 shares of TherapeuticsMD Inc, valued at $7,099 using the latest closing price.
Collins Cooper C., the Director of TherapeuticsMD Inc, purchase 1,200 shares at $1.70 during a trade that took place back on Aug 21 ’24, which means that Collins Cooper C. is holding 47,922 shares at $2,039 based on the most recent closing price.
Stock Fundamentals for TXMD
Current profitability levels for the company are sitting at:
- -3.79 for the present operating margin
- 0.52 for the gross margin
The net margin for TherapeuticsMD Inc stands at -2.08. The total capital return value is set at -0.18. Equity return is now at value -14.39, with -8.81 for asset returns.
Currently, EBITDA for the company is -8.4 million with net debt to EBITDA at -0.82. When we switch over and look at the enterprise to sales, we see a ratio of 12.1. The receivables turnover for the company is 0.48for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In conclusion, TherapeuticsMD Inc (TXMD) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
